We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,548

Changes to pharmaceuticalbiopharmaceutical patent litigation in Canada
  • DLA Piper LLP
  • Canada
  • May 23 2017

As a result of the Comprehensive Economic Trade Agreement with the European Union, significant changes to the patent linkage provisions and patent


Update on implementing CETA in Canada - What pharmaceutical companies need to know
  • Marks & Clerk
  • Canada, European Union
  • May 10 2017

The Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union was approved by all 28 EU member states in October 2016


CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly


Changes coming soon for pharmaceutical patent litigation in Canada: key points
  • DLA Piper LLP
  • Canada
  • May 25 2017

As a result of the Comprehensive Economic Trade Agreement with the European Union, significant changes to the patent linkage provisions and patent


Bill C-30 passes Senate today to usher in changes to Canadian pharma patent regulations
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 11 2017

Bill C-30 was passed by the Senate today, May 11, 2017 without amendment. Bill C-30 is the bill that will implement the Canada-European Union


Court dismisses motion for Confidentiality Order
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2017

The Court dismissed Teva's motion for a confidentiality order. The underlying proceeding is an action by Teva to recover from Janssen and others


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Competitionantitrust law
  • Dentons
  • Germany, OECD, United Kingdom, USA, Australia, Canada, China, European Union
  • February 9 2017

In the wake of the 2016 elections, we now await the decision as to who will be the "antitrust guard" at the top of the US Department


Global Government Solutions 2016: Mid-Year Outlook
  • K&L Gates
  • Australia, Canada, European Union, Germany, Global, United Kingdom, USA
  • July 1 2016

As we issue this 2016 Mid-Year Outlook, the global community has begun to wrestle in earnest with the momentous political, economic, and doing


What the Supreme Court of Canada was not told about patent utility
  • Gowling WLG
  • Canada
  • May 11 2017

On November 8, 2016 the Supreme Court of Canada (“SCC”) heard an appeal by Astrazeneca regarding the validity of a patent covering its NEXIUM product